全球細胞治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

細胞治療市場預計將從 2025 年的 3,058 萬美元成長到 2034 年的 1.5242 億美元，2026 年至 2034 年的複合年成長率為 19.54%。

再生醫學和免疫療法的突破性進展正推動全球細胞療法市場快速成長。細胞治療方法正擴大用於治療癌症、自體免疫疾病和遺傳性疾病。不斷擴大的臨床研究和監管核准正在加速其在整個醫療保健系統中的商業性化應用。

成長要素包括慢性病增多、幹細胞研究進展、生技領域投資增加。 CAR-T療法和個人化治療方案正在改變癌症的治療方式。然而，高昂的治療費用和複雜的生產流程仍然是其廣泛應用的主要挑戰。

展望未來，可擴展製造技術的創新和監管流程的改進有望加速市場成長。生物技術公司與醫療服務提供者之間的策略合作可望擴大全球應用範圍。隨著研究的不斷深入，細胞治療領域有望迎來顯著擴張。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球細胞療法市場：依技術分類

• 市場分析、洞察與預測
• 體細胞技術
• 細胞永生化技術
• 病毒載體技術
• 基因組編輯技術
• 細胞可塑性技術
• 3D技術

第5章 全球細胞療法市場：按類型分類

• 市場分析、洞察與預測
• 自體移植
• 同種異體移植

第6章 全球細胞治療市場：依細胞類型分類

• 市場分析、洞察與預測
• 幹細胞
• 非幹細胞

第7章 全球細胞療法市場：依細胞來源分類

• 市場分析、洞察與預測
• 誘導性多能幹細胞
• 骨髓
• 臍帶血衍生細胞
• 脂肪組織
• 神經幹細胞

第8章 全球細胞治療市場：依應用分類

• 市場分析、洞察與預測
• 肌肉骨骼系統
• 循環系統
• 消化器官系統
• 神經系統
• 腫瘤學
• 皮膚科
• 傷口與創傷
• 眼科
• 其他

第9章 全球細胞治療市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院和診所
• 再生醫學中心
• 診斷與研究中心
• 其他

第10章 全球細胞治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第11章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第12章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Kolon TissueGene Inc
  • JCR Pharmaceuticals Co. Ltd
  • Medipost
  • Stemedica Cell Technologies Inc
  • NuVasive Inc
  • Castle Creek Biosciences Inc
  • Cellectis
  • BioNTech IMFS
  • Pluri Biotech Ltd
  • Praxis Healthcare & Pharmaceuticals PVT. LTD
  • Pharmicell Co. Ltd

The Cell Therapy Market size is expected to reach USD 152.42 Million in 2034 from USD 30.58 Million (2025) growing at a CAGR of 19.54% during 2026-2034.

The global cell therapy market is growing rapidly due to breakthroughs in regenerative medicine and immunotherapy. Cell-based treatments are increasingly used to address cancer, autoimmune diseases, and genetic disorders. Expanding clinical research and regulatory approvals are strengthening commercial adoption across healthcare systems.

Growth drivers include rising prevalence of chronic diseases, advancements in stem cell research, and increasing investment in biotechnology. CAR-T therapies and personalized treatment approaches are transforming oncology care. However, high treatment costs and complex manufacturing processes remain key challenges for widespread accessibility.

Looking forward, technological innovation in scalable manufacturing and improved regulatory pathways will accelerate market growth. Strategic collaborations between biotech firms and healthcare providers are expected to expand global availability. The cell therapy sector is poised for substantial expansion as research continues to advance.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• Somatic Cell Technology
• Cell Immortalization Technology
• Viral Vector Technology
• Genome Editing Technology
• Cell Plasticity Technology
• Three-Dimensional Technology

By Type

• Autologous
• Allogeneic

By Cell Type

• Stem Cell
• Non-Stem Cell

By Cell Source

• Induced Pluripotent Stem Cells
• Bone Marrow
• Umbilical Cord Blood-Derived Cells
• Adipose Tissues
• Neural Stem Cells

By Application

• Musculoskeletal
• Cardiovascular
• Gastrointestinal
• Neurological
• Oncology
• Dermatology
• Wounds and Injuries
• Ocular
• Others

By End-User

• Hospitals and Clinics
• Regenerative Medicine Centres
• Diagnostic and Research Centres
• Others

COMPANIES PROFILED

• Kolon TissueGene Inc, JCR Pharmaceuticals Co Ltd, Medipost, Stemedica Cell Technologies Inc, NuVasive Inc, Castle Creek Biosciences Inc, Cellectis, BioNTech IMFS, Pluri Biotech Ltd, Praxis Healthcare Pharmaceuticals PVT LTD, Pharmicell Co Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL THERAPY MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. Somatic Cell Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Cell Immortalization Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Viral Vector Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Genome Editing Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Cell Plasticity Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Three-Dimensional Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL THERAPY MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Autologous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Allogeneic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL THERAPY MARKET: BY CELL TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Cell Type
• 6.2. Stem Cell Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Non-Stem Cell Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CELL THERAPY MARKET: BY CELL SOURCE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Cell Source
• 7.2. Induced Pluripotent Stem Cells Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Bone Marrow Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Umbilical Cord Blood-Derived Cells Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Adipose Tissues Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Neural Stem Cells Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CELL THERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Application
• 8.2. Musculoskeletal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Cardiovascular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Gastrointestinal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Neurological Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.6. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.7. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.8. Wounds and Injuries Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.9. Ocular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.10. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL CELL THERAPY MARKET: BY END-USER 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast End-user
• 9.2. Hospitals and Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Regenerative Medicine Centres Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Diagnostic and Research Centres Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL CELL THERAPY MARKET: BY REGION 2022-2034(USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Technology
  • 10.2.2 By Type
  • 10.2.3 By Cell Type
  • 10.2.4 By Cell Source
  • 10.2.5 By Application
  • 10.2.6 By End-user
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Technology
  • 10.3.2 By Type
  • 10.3.3 By Cell Type
  • 10.3.4 By Cell Source
  • 10.3.5 By Application
  • 10.3.6 By End-user
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Technology
  • 10.4.2 By Type
  • 10.4.3 By Cell Type
  • 10.4.4 By Cell Source
  • 10.4.5 By Application
  • 10.4.6 By End-user
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Technology
  • 10.5.2 By Type
  • 10.5.3 By Cell Type
  • 10.5.4 By Cell Source
  • 10.5.5 By Application
  • 10.5.6 By End-user
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 South East Asia
  • 10.5.12 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Technology
  • 10.6.2 By Type
  • 10.6.3 By Cell Type
  • 10.6.4 By Cell Source
  • 10.6.5 By Application
  • 10.6.6 By End-user
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL CELL THERAPY INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Kolon TissueGene Inc
  • 12.2.2 JCR Pharmaceuticals Co. Ltd
  • 12.2.3 Medipost
  • 12.2.4 Stemedica Cell Technologies Inc
  • 12.2.5 NuVasive Inc
  • 12.2.6 Castle Creek Biosciences Inc
  • 12.2.7 Cellectis
  • 12.2.8 BioNTech IMFS
  • 12.2.9 Pluri Biotech Ltd
  • 12.2.10 Praxis Healthcare & Pharmaceuticals PVT. LTD
  • 12.2.11 Pharmicell Co. Ltd